{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:14:30Z","timestamp":1769847270858,"version":"3.49.0"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute leukemia represents a significant therapeutic challenge, necessitating the development of innovative approaches to improve the clinical outcomes of patients. Immunotherapies have become a mainstay in the treatment of acute leukemia. Allogenic hematopoietic stem cell transplantation (allo-HSCT) is a well-established and efficacious procedure. Over time, a number of therapeutic approaches have emerged as promising strategies for achieving durable remission and have transformed the treatment of leukemia. Among the efficient immune cells engaged against leukemia, natural killer (NK) cells are innate cytotoxic cells that do not require antigenic specificity to exert their cytotoxic function. The potential of NK cells as a treatment for leukemic patients is emerging as a promising approach. They are capable of distinguishing between healthy and leukemic cells in a natural manner because of the sophisticated equilibrium between their numerous inhibitory and activating receptors. In recent years, NK cells have been found to be far more complex than expected. Indeed, the NK repertoire exhibits a remarkably high degree of phenotypic diversity, which is closely linked to the extensive polymorphism of immunogenetic KIR and HLA class I markers. It has been demonstrated that not all NK cells possess the same functional profile and that they respond to functional education mediated by these KIR-HLA molecular interactions. This review offers insights into the knowledge of NK cell diversity, with the goal of leveraging NK cell heterogeneity for the development of NK cell-based immunotherapies for acute leukemia.<\/jats:p>","DOI":"10.1186\/s12967-025-07093-y","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:29:49Z","timestamp":1762252189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia"],"prefix":"10.1186","volume":"23","author":[{"given":"Enora","family":"Ferron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Gagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5943-6990","authenticated-orcid":false,"given":"Christelle","family":"Reti\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"7093_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"7093_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, de Araujo IB, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"7093_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11912-020-00918-7","volume":"22","author":"L Marando","year":"2020","unstructured":"Marando L, Huntly BJP. Molecular landscape of acute myeloid leukemia: prognostic and therapeutic implications. Curr Oncol Rep. 2020;22:61.","journal-title":"Curr Oncol Rep"},{"key":"7093_CR4","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389.","journal-title":"Nat Genet"},{"key":"7093_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"7093_CR6","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1903\u201330.","journal-title":"Blood"},{"key":"7093_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, S\u00e1nchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217\u201339.","journal-title":"Bone Marrow Transplant"},{"key":"7093_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"7093_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541\u201352.","journal-title":"N Engl J Med"},{"key":"7093_CR10","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395:1146\u201362.","journal-title":"Lancet"},{"key":"7093_CR11","doi-asserted-by":"crossref","unstructured":"First-Ever CAR T-cell Therapy Approved in U.S. Cancer Discov. 2017;7:OF1.","DOI":"10.1158\/2159-8290.CD-NB2017-126"},{"key":"7093_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"7093_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","volume":"28","author":"GS Laszlo","year":"2014","unstructured":"Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28:143\u201353.","journal-title":"Blood Rev"},{"key":"7093_CR14","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119:6198\u2013208.","journal-title":"Blood"},{"key":"7093_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"7093_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.imlet.2006.10.009","volume":"108","author":"KS Blum","year":"2007","unstructured":"Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood: do they mirror the situation in all organs? Immunol Lett. 2007;108:45\u201351.","journal-title":"Immunol Lett"},{"key":"7093_CR17","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3389\/fimmu.2019.02078","volume":"10","author":"F Cichocki","year":"2019","unstructured":"Cichocki F, Grzywacz B, Miller JS. Human NK cell development: one road or many? Front Immunol. 2019;10:2078.","journal-title":"Front Immunol"},{"key":"7093_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2308511120","volume":"120","author":"R Sender","year":"2023","unstructured":"Sender R, Weiss Y, Navon Y, Milo I, Azulay N, Keren L, et al. The total mass, number, and distribution of immune cells in the human body. Proc Natl Acad Sci. 2023;120:e2308511120.","journal-title":"Proc Natl Acad Sci"},{"key":"7093_CR19","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1182\/blood-2002-09-2876","volume":"101","author":"TA Fehniger","year":"2003","unstructured":"Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101:3052\u20137.","journal-title":"Blood"},{"key":"7093_CR20","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.4049\/jimmunol.143.10.3183","volume":"143","author":"A Nagler","year":"1989","unstructured":"Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol. 1989;143:3183\u201391.","journal-title":"J Immunol"},{"key":"7093_CR21","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","volume":"115","author":"C Fauriat","year":"2010","unstructured":"Fauriat C, Long EO, Ljunggren H-G, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115:2167\u201376.","journal-title":"Blood"},{"key":"7093_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/83416","volume":"7","author":"K Takeda","year":"2001","unstructured":"Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001;7:94\u2013100.","journal-title":"Nat Med"},{"key":"7093_CR23","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1182\/blood.V92.11.4248","volume":"92","author":"M Bradley","year":"1998","unstructured":"Bradley M, Zeytun A, Rafi-Janajreh A, Nagarkatti PS, Nagarkatti M. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. Blood. 1998;92:4248\u201355.","journal-title":"Blood"},{"key":"7093_CR24","first-page":"218","volume":"12","author":"G Trinchieri","year":"1993","unstructured":"Trinchieri G, Valiante N. Receptors for the fc fragment of IgG on natural killer cells. Nat Immun. 1993;12:218\u201334.","journal-title":"Nat Immun"},{"key":"7093_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/0008-5472.CAN-05-2429","volume":"66","author":"JM Roda","year":"2006","unstructured":"Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 2006;66:517\u201326.","journal-title":"Cancer Res"},{"key":"7093_CR26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172:1022-1037.e14.","journal-title":"Cell"},{"key":"7093_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ijc.2910160204","volume":"16","author":"RB Herberman","year":"1975","unstructured":"Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975;16:216\u201329.","journal-title":"Int J Cancer"},{"key":"7093_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/eji.1830050208","volume":"5","author":"R Kiessling","year":"1975","unstructured":"Kiessling R, Klein E, Wigzell H. \u201cNatural\u201d killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112\u20137.","journal-title":"Eur J Immunol"},{"key":"7093_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.coi.2015.11.001","volume":"38","author":"A Iannello","year":"2016","unstructured":"Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH. Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol. 2016;38:52\u20138.","journal-title":"Curr Opin Immunol"},{"key":"7093_CR30","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","volume":"319","author":"K K\u00e4rre","year":"1986","unstructured":"K\u00e4rre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675\u20138.","journal-title":"Nature"},{"key":"7093_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/ni0508-477","volume":"9","author":"K K\u00e4rre","year":"2008","unstructured":"K\u00e4rre K. Natural killer cell recognition of missing self. Nat Immunol. 2008;9:477\u201380.","journal-title":"Nat Immunol"},{"key":"7093_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.it.2005.02.007","volume":"26","author":"C Bottino","year":"2005","unstructured":"Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol. 2005;26:221\u20136.","journal-title":"Trends Immunol"},{"key":"7093_CR33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/35642","volume":"391","author":"LL Lanier","year":"1998","unstructured":"Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 1998;391:703\u20137.","journal-title":"Nature"},{"key":"7093_CR34","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.4049\/jimmunol.168.12.6208","volume":"168","author":"M Faure","year":"2002","unstructured":"Faure M, Long EO. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol. 2002;168:6208\u201314.","journal-title":"J Immunol"},{"key":"7093_CR35","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1074-7613(00)80394-5","volume":"7","author":"M Uhrberg","year":"1997","unstructured":"Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753\u201363.","journal-title":"Immunity"},{"key":"7093_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/gene.2013.55","volume":"15","author":"SD Tao","year":"2014","unstructured":"Tao SD, He YM, Ying YL, He J, Zhu FM, Lv HJ. KIR3DL1 genetic diversity and phenotypic variation in the Chinese Han population. Genes Immun. 2014;15:8\u201315.","journal-title":"Genes Immun"},{"key":"7093_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1084\/jem.20051884","volume":"203","author":"M Yawata","year":"2006","unstructured":"Yawata M, Yawata N, Draghi M, Little A-M, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med. 2006;203:633\u201345.","journal-title":"J Exp Med"},{"key":"7093_CR38","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/eji.201243007","volume":"43","author":"K Gagne","year":"2013","unstructured":"Gagne K, Willem C, Legrand N, Djaoud Z, David G, Rettman P, et al. Both the nature of KIR3DL1 alleles and the KIR3DL1\/S1 allele combination affect the KIR3DL1 NK-cell repertoire in the French population. Eur J Immunol. 2013;43:1085\u201398.","journal-title":"Eur J Immunol"},{"key":"7093_CR39","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/cancers15102754","volume":"15","author":"N Legrand","year":"2023","unstructured":"Legrand N, Salameh P, Jullien M, Chevallier P, Ferron E, David G, et al. Non-expressed donor KIR3DL1 alleles may represent a risk factor for relapse after T-replete haploidentical hematopoietic stem cell transplantation. Cancers (Basel). 2023;15:2754.","journal-title":"Cancers (Basel)"},{"key":"7093_CR40","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.4049\/jimmunol.171.12.6640","volume":"171","author":"MJ Pando","year":"2003","unstructured":"Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol. 2003;171:6640\u20139.","journal-title":"J Immunol"},{"key":"7093_CR41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1084\/jem.182.2.605","volume":"182","author":"R Biassoni","year":"1995","unstructured":"Biassoni R, Falco M, Cambiaggi A, Costa P, Verdiani S, Pende D, et al. Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by \u201cgroup 2\u201d or \u201cgroup 1\u201d NK clones. J Exp Med. 1995;182:605\u20139.","journal-title":"J Exp Med"},{"key":"7093_CR42","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4049\/jimmunol.161.2.571","volume":"161","author":"CC Winter","year":"1998","unstructured":"Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol. 1998;161:571\u20137.","journal-title":"J Immunol"},{"key":"7093_CR43","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.4049\/jimmunol.180.6.3969","volume":"180","author":"AK Moesta","year":"2008","unstructured":"Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol. 2008;180:3969\u201379.","journal-title":"J Immunol"},{"key":"7093_CR44","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.4049\/jimmunol.1301580","volume":"191","author":"G David","year":"2013","unstructured":"David G, Djaoud Z, Willem C, Legrand N, Rettman P, Gagne K, et al. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 specificity of KIR2DS2: dominant impact of KIR2DL2\/KIR2DS2 on KIR2D NK cell repertoire formation. J Immunol. 2013;191:4778\u201388.","journal-title":"J Immunol"},{"key":"7093_CR45","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1084\/jem.180.4.1235","volume":"180","author":"M Cella","year":"1994","unstructured":"Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med. 1994;180:1235\u201342.","journal-title":"J Exp Med"},{"issue":"3","key":"7093_CR46","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1084\/jem.181.3.1133","volume":"181","author":"JE Gumperz","year":"1995","unstructured":"Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995;181(3):1133\u201344.","journal-title":"J Exp Med"},{"key":"7093_CR47","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1084\/jem.180.2.537","volume":"180","author":"V Litwin","year":"1994","unstructured":"Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med. 1994;180:537\u201343.","journal-title":"J Exp Med"},{"key":"7093_CR48","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1002\/eji.1830260845","volume":"26","author":"I Luque","year":"1996","unstructured":"Luque I, Solana R, Galiani MD, Gonz\u00e1lez R, Garc\u00eda F, L\u00f3pez de Castro JA, et al. Threonine 80 on HLA-B27 confers protection against lysis by a group of natural killer clones. Eur J Immunol. 1996;26:1974\u20137.","journal-title":"Eur J Immunol"},{"key":"7093_CR49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng934","volume":"31","author":"MP Martin","year":"2002","unstructured":"Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31:429\u201334.","journal-title":"Nat Genet"},{"key":"7093_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/BF02421207","volume":"30","author":"CA M\u00fcller","year":"1989","unstructured":"M\u00fcller CA, Engler-Blum G, Gekeler V, Steiert I, Weiss E, Schmidt H. Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw4 and Bw6. Immunogenetics. 1989;30:200\u20137.","journal-title":"Immunogenetics"},{"key":"7093_CR51","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.4049\/jimmunol.156.9.3098","volume":"156","author":"C D\u00f6hring","year":"1996","unstructured":"D\u00f6hring C, Scheidegger D, Samaridis J, Cella M, Colonna M. A human killer inhibitory receptor specific for HLA-A1,2. J Immunol. 1996;156:3098\u2013101.","journal-title":"J Immunol"},{"key":"7093_CR52","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.184.2.505","volume":"184","author":"D Pende","year":"1996","unstructured":"Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, di Donato C, et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58\/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med. 1996;184:505\u201318.","journal-title":"J Exp Med"},{"key":"7093_CR53","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.4049\/jimmunol.1300081","volume":"191","author":"JP Goodridge","year":"2013","unstructured":"Goodridge JP, Burian A, Lee N, Geraghty DE. HLA-F and MHC class i open conformers are ligands for NK cell Ig-like receptors. J Immunol. 2013;191:3553\u201362.","journal-title":"J Immunol"},{"key":"7093_CR54","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1084\/jem.189.7.1093","volume":"189","author":"S Rajagopalan","year":"1999","unstructured":"Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med. 1999;189:1093\u2013100.","journal-title":"J Exp Med"},{"key":"7093_CR55","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1084\/jem.20091010","volume":"206","author":"T Graef","year":"2009","unstructured":"Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM, et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med. 2009;206:2557\u201372.","journal-title":"J Exp Med"},{"key":"7093_CR56","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2326-6066.CIR-20-0315","volume":"9","author":"RS Bhatt","year":"2021","unstructured":"Bhatt RS, Berjis A, Konge JC, Mahoney KM, Klee AN, Freeman SS, et al. KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1. Cancer Immunol Res. 2021;9:156\u201369.","journal-title":"Cancer Immunol Res"},{"key":"7093_CR57","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1074\/mcp.TIR119.001433","volume":"18","author":"B Husain","year":"2019","unstructured":"Husain B, Ramani SR, Chiang E, Lehoux I, Paduchuri S, Arena TA, et al. A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7\u2013H3\/CD276 and PVR\/CD155. Mol Cell Proteomics. 2019;18:2310\u201323.","journal-title":"Mol Cell Proteomics"},{"key":"7093_CR58","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/eji.1830270230","volume":"27","author":"M Carretero","year":"1997","unstructured":"Carretero M, Cantoni C, Bell\u00f3n T, Bottino C, Biassoni R, Rodr\u00edguez A, et al. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol. 1997;27:563\u20137.","journal-title":"Eur J Immunol"},{"key":"7093_CR59","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1074-7613(00)80574-9","volume":"8","author":"LL Lanier","year":"1998","unstructured":"Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94\/NKG2C NK cell receptors. Immunity. 1998;8:693\u2013701.","journal-title":"Immunity"},{"key":"7093_CR60","first-page":"795","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud VM, Allan DS, O\u2019Callaghan CA, S\u00f6derstr\u00f6m K, D\u2019Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A. B C Nature. 1998;391:795\u20139.","journal-title":"B C Nature"},{"key":"7093_CR61","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.4049\/jimmunol.174.5.2878","volume":"174","author":"BK Kaiser","year":"2005","unstructured":"Kaiser BK, Barahmand-Pour F, Paulsene W, Medley S, Geraghty DE, Strong RK. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol. 2005;174:2878\u201384.","journal-title":"J Immunol"},{"key":"7093_CR62","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1182\/blood-2005-09-3682","volume":"107","author":"M Gum\u00e1","year":"2006","unstructured":"Gum\u00e1 M, Budt M, S\u00e1ez A, Brckalo T, Hengel H, Angulo A, et al. Expansion of CD94\/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood. 2006;107:3624\u201331.","journal-title":"Blood"},{"key":"7093_CR63","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.4049\/jimmunol.1301138","volume":"191","author":"Z Djaoud","year":"2013","unstructured":"Djaoud Z, David G, Bressollette C, Willem C, Rettman P, Gagne K, et al. Amplified NKG2C+ NK cells in Cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells. J Immunol. 2013;191:2708\u201316.","journal-title":"J Immunol"},{"key":"7093_CR64","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2010-04-282301","volume":"116","author":"S Lopez-Verg\u00e8s","year":"2010","unstructured":"Lopez-Verg\u00e8s S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010;116:3865\u201374.","journal-title":"Blood"},{"key":"7093_CR65","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/s41467-023-40220-1","volume":"14","author":"BD Huisman","year":"2023","unstructured":"Huisman BD, Guan N, R\u00fcckert T, Garner L, Singh NK, McMichael AJ, et al. High-throughput characterization of HLA-E-presented CD94\/NKG2x ligands reveals peptides which modulate NK cell activation. Nat Commun. 2023;14:4809.","journal-title":"Nat Commun"},{"key":"7093_CR66","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1126\/science.285.5428.730","volume":"285","author":"J Wu","year":"1999","unstructured":"Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999;285:730\u20132.","journal-title":"Science"},{"key":"7093_CR67","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727\u20139.","journal-title":"Science"},{"key":"7093_CR68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1074-7613(01)00095-4","volume":"14","author":"D Cosman","year":"2001","unstructured":"Cosman D, M\u00fcllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123\u201333.","journal-title":"Immunity"},{"key":"7093_CR69","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4049\/jimmunol.168.2.671","volume":"168","author":"CL Sutherland","year":"2002","unstructured":"Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol. 2002;168:671\u20139.","journal-title":"J Immunol"},{"key":"7093_CR70","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1084\/jem.186.7.1129","volume":"186","author":"S Sivori","year":"1997","unstructured":"Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, et al. P46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med. 1997;186:1129\u201336.","journal-title":"J Exp Med"},{"key":"7093_CR71","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1084\/jem.187.12.2065","volume":"187","author":"M Vitale","year":"1998","unstructured":"Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med. 1998;187:2065\u201372.","journal-title":"J Exp Med"},{"key":"7093_CR72","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1084\/jem.190.10.1505","volume":"190","author":"D Pende","year":"1999","unstructured":"Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med. 1999;190:1505\u201316.","journal-title":"J Exp Med"},{"key":"7093_CR73","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/35059110","volume":"409","author":"O Mandelboim","year":"2001","unstructured":"Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 2001;409:1055\u201360.","journal-title":"Nature"},{"key":"7093_CR74","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.4049\/jimmunol.168.7.3451","volume":"168","author":"R Vankayalapati","year":"2002","unstructured":"Vankayalapati R, Wizel B, Weis SE, Safi H, Lakey DL, Mandelboim O, et al. The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol. 2002;168:3451\u20137.","journal-title":"J Immunol"},{"key":"7093_CR75","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1021\/pr800747c","volume":"8","author":"M-L Hecht","year":"2009","unstructured":"Hecht M-L, Rosental B, Horlacher T, Hershkovitz O, De Paz JL, Noti C, et al. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate\/heparin sequences. J Proteome Res. 2009;8:712\u201320.","journal-title":"J Proteome Res"},{"key":"7093_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00195","volume":"4","author":"E Hammond","year":"2014","unstructured":"Hammond E, Khurana A, Shridhar V, Dredge K. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol. 2014;4:195.","journal-title":"Front Oncol"},{"key":"7093_CR77","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood-2013-03-489054","volume":"122","author":"F Baychelier","year":"2013","unstructured":"Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debr\u00e9 P, Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood. 2013;122:2935\u201342.","journal-title":"Blood"},{"key":"7093_CR78","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1084\/jem.20090681","volume":"206","author":"CS Brandt","year":"2009","unstructured":"Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, et al. The B7 family member B7\u2013H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206:1495\u2013503.","journal-title":"J Exp Med"},{"key":"7093_CR79","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1084\/jem.20030788","volume":"198","author":"C Bottino","year":"2003","unstructured":"Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198:557\u201367.","journal-title":"J Exp Med"},{"key":"7093_CR80","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48\u201357.","journal-title":"Nat Immunol"},{"key":"7093_CR81","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","volume":"172","author":"A Fuchs","year":"2004","unstructured":"Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol. 2004;172:3994\u20138.","journal-title":"J Immunol"},{"key":"7093_CR82","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1084\/jem.20150785","volume":"213","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Paniccia A, Schulick AC, Chen W, Koenig MR, Byers JT, et al. Identification of CD112R as a novel checkpoint for human T cells. J Exp Med. 2016;213:167\u201376.","journal-title":"J Exp Med"},{"key":"7093_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000266","volume":"8","author":"A Reches","year":"2020","unstructured":"Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Amikam YC, et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. J Immunother Cancer. 2020;8:e000266.","journal-title":"J Immunother Cancer"},{"key":"7093_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212443","volume":"14","author":"VM Holmes","year":"2019","unstructured":"Holmes VM, de Maluquer Motes C, Richards PT, Roldan J, Bhargava AK, Orange JS, et al. Interaction between nectin-1 and the human natural killer cell receptor CD96. PLoS ONE. 2019;14:e0212443.","journal-title":"PLoS ONE"},{"key":"7093_CR85","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1074-7613(00)70060-4","volume":"4","author":"A Shibuya","year":"1996","unstructured":"Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4:573\u201381.","journal-title":"Immunity"},{"key":"7093_CR86","doi-asserted-by":"publisher","first-page":"17858","DOI":"10.1073\/pnas.0903474106","volume":"106","author":"N Stanietsky","year":"2009","unstructured":"Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106:17858\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7093_CR87","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/ni.2850","volume":"15","author":"CJ Chan","year":"2014","unstructured":"Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15:431\u20138.","journal-title":"Nat Immunol"},{"key":"7093_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163620","author":"X Ren","year":"2022","unstructured":"Ren X, Peng M, Xing P, Wei Y, Galbo PM, Corrigan D, et al. Blockade of the immunosuppressive KIR2DL5\/PVR pathway elicits potent human NK cell\u2013mediated antitumor immunity. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI163620.","journal-title":"J Clin Invest"},{"key":"7093_CR89","doi-asserted-by":"publisher","first-page":"37964","DOI":"10.1074\/jbc.M111.285312","volume":"286","author":"C Germain","year":"2011","unstructured":"Germain C, Meier A, Jensen T, Knapnougel P, Poupon G, Lazzari A, et al. Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by pathogens and interferon-\u03b3 contributes to modulate immune responses. J Biol Chem. 2011;286:37964\u201375.","journal-title":"J Biol Chem"},{"key":"7093_CR90","doi-asserted-by":"publisher","first-page":"7791","DOI":"10.4049\/jimmunol.175.12.7791","volume":"175","author":"H Aldemir","year":"2005","unstructured":"Aldemir H, Prod\u2019homme V, Dumaurier M-J, Retiere C, Poupon G, Cazareth J, et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol. 2005;175:7791\u20135.","journal-title":"J Immunol"},{"key":"7093_CR91","doi-asserted-by":"publisher","first-page":"7796","DOI":"10.4049\/jimmunol.175.12.7796","volume":"175","author":"DB Rosen","year":"2005","unstructured":"Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol. 2005;175:7796\u20139.","journal-title":"J Immunol"},{"key":"7093_CR92","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","volume":"119","author":"LC Ndhlovu","year":"2012","unstructured":"Ndhlovu LC, Lopez-Verg\u00e8s S, Barbour JD, Jones RB, Jha AR, Long BR, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012;119:3734\u201343.","journal-title":"Blood"},{"key":"7093_CR93","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","volume":"119","author":"MK Gleason","year":"2012","unstructured":"Gleason MK, Lenvik TR, McCullar V, Felices M, O\u2019Brien MS, Cooley SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012;119:3064\u201372.","journal-title":"Blood"},{"key":"7093_CR94","doi-asserted-by":"publisher","first-page":"1229341","DOI":"10.3389\/fimmu.2023.1229341","volume":"14","author":"FR Mariotti","year":"2023","unstructured":"Mariotti FR, Ingegnere T, Landolina N, Vacca P, Munari E, Moretta L. Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells. Front Immunol. 2023;14:1229341.","journal-title":"Front Immunol"},{"key":"7093_CR95","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139:335-346.e3.","journal-title":"J Allergy Clin Immunol"},{"key":"7093_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043860","author":"SB Powers","year":"2023","unstructured":"Powers SB, Ahmed NG, Jose R, Brezgiel M, Aryal S, Bowman WP, et al. Differential expression of LLT1, SLAM receptors CS1 and 2B4 and NCR receptors NKp46 and NKp30 in pediatric acute lymphoblastic leukemia (ALL). Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24043860.","journal-title":"Int J Mol Sci"},{"key":"7093_CR97","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","volume":"90","author":"HR Koene","year":"1997","unstructured":"Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype. Blood. 1997;90:1109\u201314.","journal-title":"Blood"},{"key":"7093_CR98","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1084\/jem.188.11.2083","volume":"188","author":"MH Brown","year":"1998","unstructured":"Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med. 1998;188:2083\u201390.","journal-title":"J Exp Med"},{"key":"7093_CR99","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1073\/pnas.072065999","volume":"99","author":"S Sivori","year":"2002","unstructured":"Sivori S, Falco M, Marcenaro E, Parolini S, Biassoni R, Bottino C, et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci U S A. 2002;99:4526\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7093_CR100","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","volume":"25","author":"N Anfossi","year":"2006","unstructured":"Anfossi N, Andr\u00e9 P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25:331\u201342.","journal-title":"Immunity"},{"key":"7093_CR101","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.4049\/jimmunol.1502469","volume":"196","author":"JE Boudreau","year":"2016","unstructured":"Boudreau JE, Mulrooney TJ, Le Luduec J-B, Barker E, Hsu KC. KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV. J Immunol. 2016;196:3398\u2013410.","journal-title":"J Immunol"},{"key":"7093_CR102","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1074-7613(00)80393-3","volume":"7","author":"NM Valiante","year":"1997","unstructured":"Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D\u2019Andrea A, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739\u201351.","journal-title":"Immunity"},{"key":"7093_CR103","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2009-09-245746","volume":"115","author":"C Fauriat","year":"2010","unstructured":"Fauriat C, Ivarsson MA, Ljunggren H-G, Malmberg K-J, Micha\u00eblsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood. 2010;115:1166\u201374.","journal-title":"Blood"},{"key":"7093_CR104","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1002\/eji.200838407","volume":"38","author":"M Morvan","year":"2008","unstructured":"Morvan M, David G, S\u00e9bille V, Perrin A, Gagne K, Willem C, et al. Autologous and allogeneic HLA KIR ligand environments and activating KIR control KIR NK-cell functions. Eur J Immunol. 2008;38:3474\u201386.","journal-title":"Eur J Immunol"},{"key":"7093_CR105","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.4049\/jimmunol.181.9.6010","volume":"181","author":"C Fauriat","year":"2008","unstructured":"Fauriat C, Andersson S, Bj\u00f6rklund AT, Carlsten M, Schaffer M, Bj\u00f6rkstr\u00f6m NK, et al. Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol. 2008;181:6010\u20139.","journal-title":"J Immunol"},{"key":"7093_CR106","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aag1672","volume":"1","author":"A Horowitz","year":"2016","unstructured":"Horowitz A, Djaoud Z, Nemat-Gorgani N, Blokhuis J, Hilton HG, B\u00e9ziat V, et al. Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci Immunol. 2016;1:eaag1672.","journal-title":"Sci Immunol"},{"key":"7093_CR107","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013508","author":"J-B Le Luduec","year":"2024","unstructured":"Le Luduec J-B, Kontopoulos T, Panjwani MK, Sottile R, Liu H, Sch\u00e4fer G, et al. Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function. Blood Adv. 2024. https:\/\/doi.org\/10.1182\/bloodadvances.2024013508.","journal-title":"Blood Adv"},{"key":"7093_CR108","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nri3521","volume":"13","author":"T Pradeu","year":"2013","unstructured":"Pradeu T, Jaeger S, Vivier E. The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol. 2013;13:764\u20139.","journal-title":"Nat Rev Immunol"},{"key":"7093_CR109","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2018.09.009","volume":"49","author":"A Crinier","year":"2018","unstructured":"Crinier A, Milpied P, Escali\u00e8re B, Piperoglou C, Galluso J, Balsamo A, et al. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. Immunity. 2018;49:971-986.e5.","journal-title":"Immunity"},{"key":"7093_CR110","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","volume":"116","author":"NK Bj\u00f6rkstr\u00f6m","year":"2010","unstructured":"Bj\u00f6rkstr\u00f6m NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116:3853\u201364.","journal-title":"Blood"},{"key":"7093_CR111","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.4049\/jimmunol.171.4.1768","volume":"171","author":"JP Goodridge","year":"2003","unstructured":"Goodridge JP, Witt CS, Christiansen FT, Warren HS. KIR2DL4 (CD158d) genotype influences expression and function in NK cells. J Immunol. 2003;171:1768\u201374.","journal-title":"J Immunol"},{"key":"7093_CR112","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1182\/blood-2010-03-273656","volume":"117","author":"K Sch\u00f6nberg","year":"2011","unstructured":"Sch\u00f6nberg K, Sribar M, Enczmann J, Fischer JC, Uhrberg M. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood. 2011;117:98\u2013107.","journal-title":"Blood"},{"key":"7093_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01883-0","author":"L Rebuffet","year":"2024","unstructured":"Rebuffet L, Melsen JE, Escali\u00e8re B, Basurto-Lozada D, Bhandoola A, Bj\u00f6rkstr\u00f6m NK, et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat Immunol. 2024. https:\/\/doi.org\/10.1038\/s41590-024-01883-0.","journal-title":"Nat Immunol"},{"key":"7093_CR114","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41590-024-01884-z","volume":"25","author":"H Netskar","year":"2024","unstructured":"Netskar H, Pfefferle A, Goodridge JP, Sohlberg E, Dufva O, Teichmann SA, et al. Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping. Nat Immunol. 2024;25:1445\u201359.","journal-title":"Nat Immunol"},{"key":"7093_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11947-7","volume":"10","author":"C Yang","year":"2019","unstructured":"Yang C, Siebert JR, Burns R, Gerbec ZJ, Bonacci B, Rymaszewski A, et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat Commun. 2019;10:3931.","journal-title":"Nat Commun"},{"key":"7093_CR116","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2003-01-0019","volume":"102","author":"HR Salih","year":"2003","unstructured":"Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee H-G, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102:1389\u201396.","journal-title":"Blood"},{"key":"7093_CR117","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1038\/s41388-018-0288-y","volume":"37","author":"H Stamm","year":"2018","unstructured":"Stamm H, Klingler F, Grossjohann E-M, Muschhammer J, Vettorazzi E, Heuser M, et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene. 2018;37:5269\u201380.","journal-title":"Oncogene"},{"key":"7093_CR118","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006702","volume":"5","author":"A Horowitz","year":"2013","unstructured":"Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med. 2013;5:208ra145.","journal-title":"Sci Transl Med"},{"key":"7093_CR119","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1182\/blood-2008-03-143727","volume":"112","author":"M Yawata","year":"2008","unstructured":"Yawata M, Yawata N, Draghi M, Partheniou F, Little A-M, Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood. 2008;112:2369\u201380.","journal-title":"Blood"},{"key":"7093_CR120","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1182\/blood-2012-10-461442","volume":"121","author":"V B\u00e9ziat","year":"2013","unstructured":"B\u00e9ziat V, Traherne JA, Liu LL, Jayaraman J, Enqvist M, Larsson S, et al. Influence of KIR gene copy number on natural killer cell education. Blood. 2013;121:4703\u20137.","journal-title":"Blood"},{"key":"7093_CR121","doi-asserted-by":"publisher","first-page":"1389358","DOI":"10.3389\/fimmu.2024.1389358","volume":"15","author":"E Ferron","year":"2024","unstructured":"Ferron E, David G, Willem C, Legrand N, Salameh P, Anquetil L, et al. Multifactorial determinants of NK cell repertoire organization: insights into age, sex, KIR genotype, HLA typing, and CMV influence. Front Immunol. 2024;15:1389358.","journal-title":"Front Immunol"},{"key":"7093_CR122","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/gene.2015.15","volume":"16","author":"SE Dunphy","year":"2015","unstructured":"Dunphy SE, Guinan KJ, Chorcora CN, Jayaraman J, Traherne JA, Trowsdale J, et al. 2DL1, 2DL2 and 2DL3 all contribute to KIR phenotype variability on human NK cells. Genes Immun. 2015;16:301\u201310.","journal-title":"Genes Immun"},{"key":"7093_CR123","doi-asserted-by":"publisher","first-page":"e1927","DOI":"10.3390\/cancers12071927","volume":"12","author":"DR Makanga","year":"2020","unstructured":"Makanga DR, Rin Da, de Lorenzo F, David G, Willem C, Dubreuil L, et al. Genetic and molecular basis of heterogeneous NK cell responses against acute leukemia. Cancers (Basel). 2020;12:e1927.","journal-title":"Cancers (Basel)"},{"key":"7093_CR124","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/bloodadvances.2017015230","volume":"2","author":"S Mastaglio","year":"2018","unstructured":"Mastaglio S, Wong E, Perera T, Ripley J, Blombery P, Smyth MJ, et al. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Adv. 2018;2:335\u201346.","journal-title":"Blood Adv"},{"key":"7093_CR125","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731-1743.e13.","journal-title":"Cell"},{"key":"7093_CR126","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1226720","volume":"5","author":"EM McWilliams","year":"2016","unstructured":"McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, et al. Therapeutic CD94\/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016;5:e1226720.","journal-title":"Oncoimmunology"},{"key":"7093_CR127","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","volume":"120","author":"N Vey","year":"2012","unstructured":"Vey N, Bourhis J-H, Boissel N, Bordessoule D, Prebet T, Charbonnier A, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood. 2012;120:4317\u201323.","journal-title":"Blood"},{"key":"7093_CR128","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1182\/blood.V130.Suppl_1.889.889","volume":"130","author":"N Vey","year":"2017","unstructured":"Vey N, Dumas P-Y, Recher C, Gastaud L, Lioure B, Bulabois C-E, et al. Randomized phase 2 trial of Lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly patients (pts) with acute myeloid leukemia (AML): results of the Effikir trial. Blood. 2017;130:889.","journal-title":"Blood"},{"key":"7093_CR129","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1016\/S2352-3026(20)30144-7","volume":"7","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, et al. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020;7:e523\u201333.","journal-title":"Lancet Haematol"},{"key":"7093_CR130","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2021.279851","volume":"107","author":"M Cerrano","year":"2022","unstructured":"Cerrano M, Bonifacio M, Olivi M, Curti A, Malagola M, Dargenio M, et al. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. Haematologica. 2022;107:996\u20139.","journal-title":"Haematologica"},{"key":"7093_CR131","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puy\u00f3 P, et al. Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024;144:2237\u201347.","journal-title":"Blood"},{"key":"7093_CR132","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/2326-6066.CIR-21-0843","volume":"10","author":"N Colomar-Carando","year":"2022","unstructured":"Colomar-Carando N, Gauthier L, Merli P, Loiacono F, Canevali P, Falco M, et al. Exploiting natural killer cell engagers to control pediatric B-cell precursor acute lymphoblastic leukemia. Cancer Immunol Res. 2022;10:291\u2013302.","journal-title":"Cancer Immunol Res"},{"key":"7093_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00982-7","author":"A Fenis","year":"2024","unstructured":"Fenis A, Demaria O, Gauthier L, Vivier E, Narni-Mancinelli E. New immune cell engagers for cancer immunotherapy. Nat Rev Immunol. 2024. https:\/\/doi.org\/10.1038\/s41577-023-00982-7.","journal-title":"Nat Rev Immunol"},{"key":"7093_CR134","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1016\/j.ymthe.2021.06.018","volume":"29","author":"E Chiu","year":"2021","unstructured":"Chiu E, Felices M, Cichocki F, Davis Z, Wang H, Tuninga K, et al. Anti-NKG2C\/IL-15\/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia. Mol Ther. 2021;29:3410\u201321.","journal-title":"Mol Ther"},{"key":"7093_CR135","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-16-0350","volume":"22","author":"U Reusch","year":"2016","unstructured":"Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, et al. Characterization of CD33\/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin Cancer Res. 2016;22:5829\u201338.","journal-title":"Clin Cancer Res"},{"key":"7093_CR136","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051\u20137.","journal-title":"Blood"},{"key":"7093_CR137","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28:955\u20139.","journal-title":"J Clin Oncol"},{"key":"7093_CR138","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384.","journal-title":"Nat Med"},{"key":"7093_CR139","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15:163.","journal-title":"J Hematol Oncol"},{"key":"7093_CR140","doi-asserted-by":"publisher","first-page":"4054815","DOI":"10.1155\/2018\/4054815","volume":"2018","author":"S Matosevic","year":"2018","unstructured":"Matosevic S. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies. J Immunol Res. 2018;2018:4054815.","journal-title":"J Immunol Res"},{"key":"7093_CR141","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15:8439.","journal-title":"Nat Commun"},{"key":"7093_CR142","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137:624\u201336.","journal-title":"Blood"},{"key":"7093_CR143","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.stem.2024.06.011","volume":"31","author":"Q Hammer","year":"2024","unstructured":"Hammer Q, Perica K, Mbofung RM, van Ooijen H, Martin KE, Momayyezi P, et al. Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell Stem Cell. 2024;31:1376-1386.e8.","journal-title":"Cell Stem Cell"},{"key":"7093_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02003-x","author":"Y Li","year":"2022","unstructured":"Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022. https:\/\/doi.org\/10.1038\/s41591-022-02003-x.","journal-title":"Nat Med"},{"key":"7093_CR145","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1021\/ja710644g","volume":"130","author":"D Rabuka","year":"2008","unstructured":"Rabuka D, Forstner MB, Groves JT, Bertozzi CR. Noncovalent cell surface engineering: incorporation of bioactive synthetic glycopolymers into cellular membranes. J Am Chem Soc. 2008;130:5947\u201353.","journal-title":"J Am Chem Soc"},{"key":"7093_CR146","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.chembiol.2013.09.010","volume":"21","author":"JE Hudak","year":"2014","unstructured":"Hudak JE, Bertozzi CR. Glycotherapy: new advances inspire a reemergence of glycans in medicine. Chem Biol. 2014;21:16\u201337.","journal-title":"Chem Biol"},{"key":"7093_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00631","volume":"8","author":"JP Veluchamy","year":"2017","unstructured":"Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J. The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments. Front Immunol. 2017;8:631.","journal-title":"Front Immunol"},{"issue":"4","key":"7093_CR148","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5966\/sctm.2012-0084","volume":"2","author":"DA Knorr","year":"2013","unstructured":"Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJN, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274\u201383.","journal-title":"Stem Cells Transl Med"},{"key":"7093_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55239-y","volume":"9","author":"L Herrera","year":"2019","unstructured":"Herrera L, Santos S, Vesga MA, Anguita J, Martin-Ruiz I, Carrascosa T, et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci Rep. 2019;9:18729.","journal-title":"Sci Rep"},{"key":"7093_CR150","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/stem.2230","volume":"34","author":"DL Hermanson","year":"2016","unstructured":"Hermanson DL, Bendzick L, Pribyl L, McCullar V, Vogel RI, Miller JS, et al. Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer. Stem Cells. 2016;34:93\u2013101.","journal-title":"Stem Cells"},{"key":"7093_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841107","volume":"13","author":"BH Goldenson","year":"2022","unstructured":"Goldenson BH, Hor P, Kaufman DS. Ipsc-derived natural killer cell therapies - expansion and targeting. Front Immunol. 2022;13:841107.","journal-title":"Front Immunol"},{"key":"7093_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.561553","volume":"11","author":"BH Goldenson","year":"2020","unstructured":"Goldenson BH, Zhu H, Wang YM, Heragu N, Bernareggi D, Ruiz-Cisneros A, et al. Umbilical cord blood and iPSC-derived natural killer cells demonstrate key differences in cytotoxic activity and KIR profiles. Front Immunol. 2020;11:561553.","journal-title":"Front Immunol"},{"key":"7093_CR153","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/152581601750288975","volume":"10","author":"G Maki","year":"2001","unstructured":"Maki G, Klingemann HG, Martinson JA, Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res. 2001;10:369\u201383.","journal-title":"J Hematother Stem Cell Res"},{"key":"7093_CR154","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652\u20138.","journal-title":"Leukemia"},{"key":"7093_CR155","first-page":"2859","volume":"4","author":"Y Yan","year":"1998","unstructured":"Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res. 1998;4:2859\u201368.","journal-title":"Clin Cancer Res"},{"key":"7093_CR156","first-page":"266","volume":"23","author":"KP Fabian","year":"2021","unstructured":"Fabian KP, Hodge JW. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. Mol Ther. 2021;23:266\u201376.","journal-title":"Mol Ther"},{"key":"7093_CR157","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fimmu.2017.00458","volume":"8","author":"M Granzin","year":"2017","unstructured":"Granzin M, Wagner J, K\u00f6hl U, Cerwenka A, Huppert V, Ullrich E. Shaping of natural killer cell antitumor activity by ex vivo cultivation. Front Immunol. 2017;8:458.","journal-title":"Front Immunol"},{"key":"7093_CR158","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","volume":"107","author":"YT Bryceson","year":"2006","unstructured":"Bryceson YT, March ME, Ljunggren H-G, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107:159\u201366.","journal-title":"Blood"},{"key":"7093_CR159","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1084\/jem.20120944","volume":"209","author":"J Ni","year":"2012","unstructured":"Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12\/15\/18-preactivated NK cells against established tumors. J Exp Med. 2012;209:2351\u201365.","journal-title":"J Exp Med"},{"key":"7093_CR160","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","volume":"120","author":"R Romee","year":"2012","unstructured":"Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012;120:4751\u201360.","journal-title":"Blood"},{"key":"7093_CR161","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/eji.201747128","volume":"48","author":"E-M Ewen","year":"2018","unstructured":"Ewen E-M, Pahl JHW, Miller M, Watzl C, Cerwenka A. KIR downregulation by IL-12\/15\/18 unleashes human NK cells from KIR\/HLA-I inhibition and enhances killing of tumor cells. Eur J Immunol. 2018;48:355\u201365.","journal-title":"Eur J Immunol"},{"key":"7093_CR162","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/1078-0432.CCR-15-1419","volume":"22","author":"M Rosario","year":"2016","unstructured":"Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, et al. The IL-15-based ALT-803 complex enhances Fc\u03b3RIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res. 2016;22:596\u2013608.","journal-title":"Clin Cancer Res"},{"key":"7093_CR163","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8:357ra123.","journal-title":"Sci Transl Med"},{"key":"7093_CR164","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1182\/blood.2021013972","volume":"139","author":"JJ Bednarski","year":"2022","unstructured":"Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood. 2022;139:1670\u201383.","journal-title":"Blood"},{"key":"7093_CR165","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/0008-5472.CAN-17-0799","volume":"77","author":"F Cichocki","year":"2017","unstructured":"Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, et al. GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Res. 2017;77:5664\u201375.","journal-title":"Cancer Res"},{"key":"7093_CR166","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4049\/jimmunol.178.1.85","volume":"178","author":"J North","year":"2007","unstructured":"North J, Bakhsh I, Marden C, Pittman H, Addison E, Navarrete C, et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol. 2007;178:85\u201394.","journal-title":"J Immunol"},{"key":"7093_CR167","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","volume":"24","author":"TA Fehniger","year":"2018","unstructured":"Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, et al. A phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2018;24:1581\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7093_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050451","volume":"13","author":"A Maia","year":"2024","unstructured":"Maia A, Tarannum M, L\u00e9rias JR, Piccinelli S, Borrego LM, Maeurer M, et al. Building a better defense: expanding and improving natural killer cells for adoptive cell therapy. Cells. 2024;13:451.","journal-title":"Cells"},{"issue":"5","key":"7093_CR169","volume":"2024","author":"F Gao","year":"2020","unstructured":"Gao F, Mora MC, Constantinides M, Co\u00ebnon L, Multrier C, Vaillant L, et al. Feeder cell training shapes the phenotype and function of in vitro expanded natural killer cells. MedComm. 2020;2024(5):e740.","journal-title":"MedComm"},{"key":"7093_CR170","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood-2004-09-3548","volume":"105","author":"D Pende","year":"2005","unstructured":"Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, et al. Analysis of the receptor-ligand interactions in the natural killer\u2013mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood. 2005;105:2066\u201373.","journal-title":"Blood"},{"key":"7093_CR171","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10875-025-01913-y","volume":"45","author":"E Ferron","year":"2025","unstructured":"Ferron E, Jullien M, Braud M, David G, Fourgeux C, Bastien M, et al. Broad diversity of molecular interactions engaged between NK cells and acute leukemic cells: KIR2DL5 limits drastically NK cell responses against leukemic cells. J Clin Immunol. 2025;45:118.","journal-title":"J Clin Immunol"},{"key":"7093_CR172","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3324\/haematol.2013.101931","volume":"99","author":"GF Torelli","year":"2014","unstructured":"Torelli GF, Peragine N, Raponi S, Pagliara D, De Propris MS, Vitale A, et al. Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica. 2014;99:1248\u201354.","journal-title":"Haematologica"},{"key":"7093_CR173","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03766-7","volume":"73","author":"K Seel","year":"2024","unstructured":"Seel K, Schirrmann RL, Stowitschek D, Ioseliani T, Roiter L, Knierim A, et al. Blockade of the TIGIT-CD155\/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia. Cancer Immunol Immunother. 2024;73:180.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"7093_CR174","first-page":"1107","volume":"109","author":"Y Kaito","year":"2023","unstructured":"Kaito Y, Sugimoto E, Nakamura F, Tsukune Y, Sasaki M, Yui S, et al. Immune checkpoint molecule DNAM-1\/CD112 axis is a novel target for NK-cell therapy in acute myeloid leukemia. Haematologica. 2023;109(4):1107.","journal-title":"Haematologica"},{"key":"7093_CR175","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1151","volume":"9","author":"B Foley","year":"2020","unstructured":"Foley B, Ta C, Barnes S, de Jong E, Nguyen M, Cheung LC, et al. Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia. Clin Transl Immunol. 2020;9:e1151.","journal-title":"Clin Transl Immunol"},{"key":"7093_CR176","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572:254\u20139.","journal-title":"Nature"},{"key":"7093_CR177","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","volume":"109","author":"C Fauriat","year":"2007","unstructured":"Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007;109:323\u201330.","journal-title":"Blood"},{"key":"7093_CR178","doi-asserted-by":"publisher","first-page":"1023510","DOI":"10.3389\/fonc.2022.1023510","volume":"12","author":"L Valenzuela-V\u00e1zquez","year":"2022","unstructured":"Valenzuela-V\u00e1zquez L, Nu\u00f1ez-Enriquez JC, S\u00e1nchez-Herrera J, Medina-Sanson A, P\u00e9rez-Saldivar ML, Jim\u00e9nez-Hern\u00e1ndez E, et al. NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia. Front Oncol. 2022;12:1023510.","journal-title":"Front Oncol"},{"key":"7093_CR179","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.4049\/jimmunol.1500262","volume":"195","author":"Z Khaznadar","year":"2015","unstructured":"Khaznadar Z, Boissel N, Agaugu\u00e9 S, Henry G, Cheok M, Vignon M, et al. Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion. J Immunol. 2015;195:2580\u201390.","journal-title":"J Immunol"},{"key":"7093_CR180","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020459118","volume":"118","author":"A-S Chretien","year":"2021","unstructured":"Chretien A-S, Devillier R, Granjeaud S, Cordier C, Demerle C, Salem N, et al. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. Proc Natl Acad Sci U S A. 2021;118:e2020459118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7093_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200870","volume":"32","author":"AA van Vliet","year":"2024","unstructured":"van Vliet AA, van den Hout MGCN, Steenmans D, Duru AD, Georgoudaki A-M, de Gruijl TD, et al. Bulk and single-cell transcriptomics identify gene signatures of stem cell-derived NK cell donors with superior cytolytic activity. Mol Ther Oncol. 2024;32:200870.","journal-title":"Mol Ther Oncol"},{"key":"7093_CR182","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111419","volume":"14","author":"R Meazza","year":"2023","unstructured":"Meazza R, Ruggeri L, Guolo F, Minetto P, Canevali P, Loiacono F, et al. Donor selection for adoptive immunotherapy with NK cells in AML patients: comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire. Front Immunol. 2023;14:1111419.","journal-title":"Front Immunol"},{"key":"7093_CR183","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005577","volume":"10","author":"A Haroun-Izquierdo","year":"2022","unstructured":"Haroun-Izquierdo A, Vincenti M, Netskar H, van Ooijen H, Zhang B, Bendzick L, et al. Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia. J Immunother Cancer. 2022;10:e005577.","journal-title":"J Immunother Cancer"},{"key":"7093_CR184","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00607","volume":"7","author":"O Hatton","year":"2016","unstructured":"Hatton O, Strauss-Albee DM, Zhao NQ, Haggadone MD, Pelpola JS, Krams SM, et al. NKG2A-expressing natural killer cells dominate the response to autologous lymphoblastoid cells infected with Epstein-Barr virus. Front Immunol. 2016;7:607.","journal-title":"Front Immunol"},{"key":"7093_CR185","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097\u2013100.","journal-title":"Science"},{"key":"7093_CR186","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.celrep.2019.10.058","volume":"29","author":"A Pfefferle","year":"2019","unstructured":"Pfefferle A, Jacobs B, Netskar H, Ask EH, Lorenz S, Clancy T, et al. Intra-lineage plasticity and functional reprogramming maintain natural killer cell repertoire diversity. Cell Rep. 2019;29:2284-2294.e4.","journal-title":"Cell Rep"},{"key":"7093_CR187","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1189\/jlb.1HI0116-036R","volume":"100","author":"P Rettman","year":"2016","unstructured":"Rettman P, Willem C, David G, Riou R, Legrand N, Esbelin J, et al. New insights on the natural killer cell repertoire from a thorough analysis of cord blood cells. J Leukoc Biol. 2016;100:471\u20139.","journal-title":"J Leukoc Biol"},{"key":"7093_CR188","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007202","volume":"11","author":"BA Hussein","year":"2023","unstructured":"Hussein BA, Kristenson L, Pesce S, W\u00f6hr A, Tian Y, Hallner A, et al. NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells. J Immunother Cancer. 2023;11:e007202.","journal-title":"J Immunother Cancer"},{"key":"7093_CR189","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154334","volume":"132","author":"RM Shapiro","year":"2022","unstructured":"Shapiro RM, Birch GC, Hu G, Vergara Cadavid J, Nikiforow S, Baginska J, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022;132:e154334.","journal-title":"J Clin Invest"},{"key":"7093_CR190","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1172\/JCI125916","volume":"129","author":"A Merino","year":"2019","unstructured":"Merino A, Zhang B, Dougherty P, Luo X, Wang J, Blazar BR, et al. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. J Clin Invest. 2019;129:3770\u201385.","journal-title":"J Clin Invest"},{"key":"7093_CR191","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.3390\/cancers12123595","volume":"12","author":"L Dubreuil","year":"2020","unstructured":"Dubreuil L, Maniangou B, Chevallier P, Qu\u00e9m\u00e9ner A, Legrand N, B\u00e9n\u00e9 MC, et al. Centromeric KIR AA individuals harbor particular KIR alleles conferring beneficial NK cell features with implications in haplo-identical hematopoietic stem cell transplantation. Cancers (Basel). 2020;12:3595.","journal-title":"Cancers (Basel)"},{"key":"7093_CR192","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.3390\/cancers13153767","volume":"13","author":"L Dubreuil","year":"2021","unstructured":"Dubreuil L, Chevallier P, Reti\u00e8re C, Gagne K. Relevance of Polymorphic KIR and HLA Class I Genes in NK-Cell-Based Immunotherapies for Adult Leukemic Patients. Cancers (Basel). 2021;13:3767.","journal-title":"Cancers (Basel)"},{"key":"7093_CR193","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.4049\/jimmunol.0803323","volume":"183","author":"MJJ Rose","year":"2009","unstructured":"Rose MJJ, Brooks AG, Stewart LA, Nguyen TH, Schwarer AP. Killer Ig-like receptor ligand mismatch directs NK cell expansion in vitro. J Immunol. 2009;183:4502\u20138.","journal-title":"J Immunol"},{"key":"7093_CR194","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","volume":"101","author":"JM Brenchley","year":"2003","unstructured":"Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101:2711\u201320.","journal-title":"Blood"},{"key":"7093_CR195","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/cei\/uxae040","volume":"217","author":"LP Covre","year":"2024","unstructured":"Covre LP, Fantecelle CH, Queiroz AM, Fardin JM, Miranda PH, Henson S, et al. NKG2C+CD57+ natural killer cells with senescent features are induced during cutaneous leishmaniasis and accumulate in patients with lesional healing impairment. Clin Exp Immunol. 2024;217:279\u201390.","journal-title":"Clin Exp Immunol"},{"key":"7093_CR196","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41590-018-0049-7","volume":"19","author":"E Patin","year":"2018","unstructured":"Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, et al. Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Nat Immunol. 2018;19:302\u201314.","journal-title":"Nat Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07093-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07093-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07093-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:27:00Z","timestamp":1762295220000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07093-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":196,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7093"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07093-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1218"}}